The American Journal of Managed Care® spoke with Jane L. Frederick, MD, FACOG, a reproductive endocrinologist and fertility specialist, about the changing landscape of cancer treatment, partnering with oncologists, and helping patients gain financial assistance for their fertility preservation and treatment.
A new study highlights how the beliefs of surgeons and radiation oncologists influences radiotherapy use in early-stage breast cancer among older women.
A new study in the journal BMJ concludes that most oncology drugs approved by the European Medicines Agency between 2009 and 2013 failed to display a benefit on survival or quality of life, even at 3.3 years following market entry.
A research study conducted in a mouse mammary cancer model has found that optimal timing, based on sequencing of immunotherapy agents, is important for treatment efficacy.
A new survey conducted by The Health Management Academy has identified a rapid investment by leading healthcare systems in precision medicine programs, with significant expectations of the impact of real-world outcomes on physician decision making.
October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.
Key lessons learnt at the National Comprehensive Cancer Network's policy meeting: Redefining Quality Measurement in Oncology.
Ensuring access to appropriate data and then using the information to improve healthcare outcomes remains an ongoing challenge-this was the conclusion drawn by panelists participating at the National Comprehensive Cancer Network’s Oncology Policy Summit on Redefining Quality Measurement in Oncology.
Combining positron emission tomography and computed tomography early in the treatment plan for patients diagnosed with advanced melanoma can help identify the potential benefit of a specific immunotherapy and avoid the risk of non-beneficial intervention.
At the National Comprehensive Cancer Network's Oncology Policy Summit, a physician administrator from the MD Anderson Cancer Center discussed weaving the patient focus into outcomes measurements.
Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.
A new paper in JCO Precision Oncology evaluated the impact of the support provided by a decision support team on clinical decision making and trial enrollment.
Physicians across different institutes who have been involved in clinical trials of chimeric antigen receptor (CAR) T cells in B-cell lymphomas have developed a guideline for monitoring and managing the symptoms associated with this treatment.
Robert Dubois, MD, PhD, chief science officer of the National Pharmaceutical Council (NPC), has advised the Department of Veterans Affairs (VA) to be cautious when using the information provided by the Institute for Clinical and Economic Review (ICER)’s drug assessment reports to inform formulary decisions.
New results published in CDC’s Morbidity and Mortality Weekly Report have identified a surge in pediatric acute lymphoblastic leukemia (ALL) during the period 2001 to 2008, followed by stabilization during 2008 to 2014.
Cabazitaxel can now be used at a dose of 20 mg/m2 every 3 weeks in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have received a docetaxel-based treatment regimen.
The FDA has approved bevacizumab-awwb (Mvasi) as a treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.
A recent survey conducted by Integra Connect has found that a majority of specialty physicians have not yet invested in operational changes that may be essential for their success under value-based care reimbursement models.
CheckMate-214 results presented at the European Society of Medical Oncology meeting show improved overall survival in patients with renal cell carcinoma treated with the nivolumab-ipilimumab combination, compared with sunitinib.
Oncologist- as well as patient-initiated conversations on the cost of cancer care led to conversations on cost-reducing strategies 38% of the time, according to a new study published in the Journal of Oncology Practice.
Bristol-Myers Squibb announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.
A single blood draw that combines the detection of DNA and protein markers could be more sensitive to the earlier detection of pancreatic cancer, according to a new study published in Proceedings of the National Academy of Sciences.
Cellectis, a clinical-stage biotechnology company, was asked by the FDA to place a clinical hold on 2 phase 1 trials evaluating its allogeneic chimeric antigen receptor-T (CAR-T) cell treatments following the report of a fatality in the first patient treated in one of the studies.
A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.
Results of a combination trial evaluating epacadostat with pembrolizumab in advanced melanoma, to be presented at the upcoming European Society for Medical Oncology (ESMO) 2017 Congress, has found that the treatment is well tolerated and has promising clinical activity.
A study published in JCO Precision Oncology has identified an association between genetic inheritance and patients’ response to efficacy and toxicity in the phase 3 ECOG-ACRIN-5103 trial.
Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.
A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.
According to a new study published in Cancer, an annual screening mammogram starting at age 40 has the greatest impact on reducing mortality.
High out-of-pocket (OOP) medical costs in survivors of childhood cancer can influence their treatment choices and care-related behavior, and ultimately affect their health outcomes, according to a study published in the Journal of Clinical Oncology.